A Rare Variant Identified Within the GluN2B C-Terminus in a Patient with Autism Affects NMDA Receptor Surface Expression and Spine Density

Shuxi Liu, National Institutes of Health
Liang Zhou, National Institutes of Health
Hongjie Yuan, Emory University
Marta Vieira, National Institutes of Health
Antonio Sanz-Clemente, National Institutes of Health
John D. Badger, National Institutes of Health
Wei Lu, National Institutes of Health
Stephen Traynelis, Emory University
Katherine W. Roche, National Institutes of Health

Journal Title: Journal of Neuroscience Nursing
Volume: Volume 37, Number 15
Publisher: Lippincott, Williams & Wilkins | 2017-04-12, Pages 4093-4102
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1523/JNEUROSCI.0827-16.2017
Permanent URL: https://pid.emory.edu/ark:/25593/s5zzw

Final published version: http://dx.doi.org/10.1523/JNEUROSCI.0827-16.2017

Copyright information:
© 2017 the authors.

Accessed November 26, 2017 2:57 AM EST
A Rare Variant Identified Within the GluN2B C-Terminus in a Patient with Autism Affects NMDA Receptor Surface Expression and Spine Density


1Receptor Biology Section and 2Synapse and Neural Circuit Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, 3Department of Pharmacology and 4Center for Functional Evaluation of Rare Variants (CFERV), Emory University School of Medicine, Atlanta, Georgia 30322, and 5Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611

NMDA receptors (NMDARs) are ionotropic glutamate receptors that are crucial for neuronal development and higher cognitive processes. NMDAR dysfunction is involved in a variety of neurological and psychiatric diseases; however, the mechanistic link between the human pathology and NMDAR dysfunction is poorly understood. Rare missense variants within NMDAR subunits have been identified in numerous patients with mental or neurological disorders. We specifically focused on the GluN2B NMDAR subunit, which is highly expressed in the hippocampus and cortex throughout development. We analyzed several variants located in the GluN2B C terminus and found that three variants in patients with autism (S1415L) or schizophrenia (L1424F and S1452F) (S1413L, L1422F, and S1450F in rodents, respectively) displayed impaired binding to membrane-associated guanylate kinase (MAGUK) proteins. In addition, we observed a deficit in surface expression for GluN2B S1413L. Furthermore, there were fewer dendritic spines in GluN2B S1413L-expressing neurons. Importantly, synaptic NMDAR currents in neurons transfected with GluN2B S1413L in GluN2A/B-deficient mouse brain slices revealed only partial rescue of synaptic current amplitude. Functional properties of GluN2B S1413L in recombinant systems revealed no change in receptor properties, consistent with synaptic defects being the result of reduced trafficking and targeting of GluN2B S1413L to the synapse. Therefore, we find that GluN2B S1413L displays deficits in NMDAR trafficking, synaptic currents, and spine density, raising the possibility that this mutation may contribute to the phenotype in this autism patient. More broadly, our research demonstrates that the targeted study of certain residues in NMDARs based on rare variants identified in patients is a powerful approach to studying receptor function.

Key words: dendritic morphology; human diseases; MAGUK binding; NMDA receptor; surface expression; synaptic function

Introduction

NMDA receptors (NMDARs) are ionotropic glutamate receptors that regulate neurotransmission, neuronal development, and plasticity in the brain (Traynelis et al., 2010). NMDARs are heterotetramers composed of two GluN1 and two GluN2/3 subunits and are primarily located at the postsynaptic density (PSD) at synaptic junctions. The redundancy of NMDAR subunits provides a mechanism for compensating for functional changes in particular subunits, which could be important for understanding the role of specific subunits in diverse neurological and psychiatric diseases.
excitatory synapses in the CNS. The C-terminal domains of GluN2 subunits play an important role in regulating surface expression, synaptic stability, and removal of NMDARs from the synapse. In particular, GluN2B has many residues within the C terminus that modulate GluN2B trafficking and synaptic targeting. The last 4 aa (1479–1482: ESDV) of GluN2B constitute a well-characterized PDZ-binding domain that interacts with PSD-95 family members, which are membrane-associated guanylate kinase proteins (MAGUKs) (Kim and Sheng, 2004). GluN2B is phosphorylated by casein kinase 2 (CK2) on serine 1480 within the PDZ ligand, which eliminates MAGUK binding via that domain (Chung et al., 2004). Phosphorylation of GluN2B S1480 first increases during development and upon neuronal activity and mediates the lateral movement of NMDARs from the PSD to extrasynaptic areas, where they undergo endocytosis (Chen et al., 2012). Once GluN2B–containing NMDARs are removed, GluN2A-containing NMDARs are inserted to the PSD and become a major NMDAR subtype at mature synapses, resulting in faster NMDAR kinetics. Reduction of S1480 phosphorylation is observed at later developmental stages (Sanz-Clemente et al., 2010). Several regions of the GluN2C C terminus upstream of the PDZ ligand have also been identified as being important for protein binding and synaptic expression, including a CaMKII-binding site. When CaMKII is activated, it binds to GluN2B and recruits CK2, resulting in phosphorylation of GluN2B S1480 and destabilization of synaptic GluN2B (Sanz-Clemente et al., 2013b). In addition, secondary non-PDZ-binding sites have been identified for PSD-95 between aa residues 1157 and 1458 on GluN2B (Cousins and Stephenson, 2012) and for another MAGUK protein, SAP102, in a region including aa residues 1391 and 1392 (Chen et al., 2012). Loss of GluN2B-containing NMDARs leads to early neonatal mortality in mice (Kutsuwada et al., 1996). Conditional deletion of GluN2B at the bed nucleus of the stria terminalis eliminates LTP and actions of ethanol on NMDAR function (Wills et al., 2012). In addition to null mutations, there are multiple studies reporting GluN2B missense variants in patients with schizophrenia, autism, epilepsy, mental retardation, and other neurological or psychiatric diseases (Ohtsuki et al., 2001; Arning et al., 2007; Allen et al., 2008; Freunssch et al., 2013; Epi et al., 2013; Lemke et al., 2014; Hamdan et al., 2014; Andreoli et al., 2014; Zhu et al., 2015; Swanger et al., 2016; for review, see Yuan et al., 2015 and Hu et al., 2016). However, pathological and biological consequences of these missense variants have not been well-characterized in humans or animal models.

Third-generation deep sequencing is a high-throughput technique that enables the detection of single novel variants from individual patients. From the existing literature and the public cosmic database, we obtained a list of rare variants in NMDAR subunits and specifically focused on those identified within the GluN2B C-terminal domain (Parsons et al., 2008; Tarabeux et al., 2011; Myers et al., 2011). We tested several GluN2B variants with the most dramatic amino acid changes in regard to charge, size, and polarity of the side chain. Three GluN2B variants, S1415L (S1413L in rat and mouse), L1424F (L1422F in rat and mouse), and S1452F (S1450F in rat and mouse), exhibited impaired binding affinity to PSD-95 and SAP102. Moreover, GluN2B S1413L showed reduced surface expression in hippocampal neurons. GluN2B S1413L-expressing neurons also had reduced dendritic spine density compared with neurons expressing GluN2B WT. Because GluN2B S1413L displayed abnormal phenotypes in all of the assays we performed, we further characterized this variant to investigate functional properties. We expressed GluN2B WT and S1413L in slices prepared from GluN2A/B conditional knockout mice and found that GluN2B S1413L only partially rescued synaptic NMDAR currents compared with full recovery with GluN2B WT. Our results demonstrate that serine 1413 is important in maintaining normal GluN2B function and subcellular localization and in regulating synaptic activity. These findings also provide mechanistic insight into neurological diseases caused by missense variants in the GluN2B C terminus.

Materials and Methods

Neuronal cultures, antibodies, and reagents. We adhered to the guidelines of the National Institutes of Health’s Animal Research Advisory Committee regarding the care and use of animals for this study. For immunocytochemistry experiments, we used primary cultured hippocampal neurons from embryonic day 18 (E18) Sprague Dawley rats of either sex as described previously (Roche and Huganir, 1995). C57BL/6 GluN2A/ GluN2B floxed mice (Gray et al., 2011) of either sex were bred in pairs and used to prepare neuronal cultures for recording NMDAR currents. Brain tissue from WT adult C57BL/6 mice of either sex was used for GST-pull-down assays.

PSD-95 and SAP102 antibodies were from NeuroMab. Anti-GFP and secondary antibodies for immunofluorescence were from Invitrogen. GFP-tagged rat GluN2B cDNA was kindly provided by Dr. Stefano Vicini (Georgetown University). Point mutations were made by PCR with targeted primers. Portions of the GluN2B C terminus was amplified from rat GluN2B cDNA using PCR and the resulting product was subcloned in frame into the pGEX-4T1 vector at the EcoRI and XhoI sites.

Preparation of synaptosomes from mouse brain and GST pull-down assays. We followed previously published procedures (Sanz-Clemente et al., 2010) to perform membrane fractionation of forebrain collected from 3- to 6-month-old rats. Tissue was homogenized in cold 10 mm Tris–HCl (pH 7.5), 1 mm EDTA, 1 mm EGTA, 1 mm Na3VO4), supplemented with 0.32 M sucrose. Buffer was supplemented with phosphatase inhibitors (P5726 and P0044; Sigma-Aldrich) and protease inhibitors (cComplete EDTA-free, 05056499010; Roche). The homogenate was centrifuged at 1000 × g for 10 min at 4°C to remove nuclei. The P2 fraction was isolated by taking the supernatant and centrifuging at 10,000 × g for 20 min at 4°C. The P2 fraction was then solubilized in TEVP buffer with 35.6 mm sucrose and 1% SDS for 30 min at 37°C. Solubilized P2 fraction was neutralized with 3 volumes of TEVP buffer containing 35.6 mm sucrose and 1% Triton X-100 for 30 min on ice and sonicated on ice for 15 s to shear DNA. The solubilized P2 solution was centrifuged at 30,000 × g for 10 min to exclude insoluble debris and the supernatant was incubated with GST-GluN2B.

A plasmid (pGEX-4T1) containing the GST-rat GluN2B (residues 1315–1482) WT, S1413L, L1422F, or S1450F mutants was transformed into BL-21 E. coli. GluN2B ΔSTOP is the same construct described (V1482Stop) in Sanz-Clemente et al. (2010). Protein expression was induced by IPTG; the bacteria were collected, lysed, and GST-GluN2B fusion proteins present in the supernatant were enriched by isolating the fusion proteins on glutathione Sepharose-4B beads (GE Healthcare). The TEVP bomb from mouse brain was incubated with GST-GluN2B (WT or mutant) Sepharose beads for 2 h at 4°C. After three washes with PBS, bound proteins were eluted and immunoblotted for PSD-95 or SAP102.
to evaluate the protein interaction. The amount of GST-GluN2B fusion protein was determined by staining with GelCode Blue (Thermo Fisher).

**Immunofluorescence microscopy.** Surface receptors were analyzed using a fluorescence-based antibody binding assay as described previously (Sanz-Clemente et al., 2010). Briefly, hippocampal neurons were transfected with GFP-GluN2B at d in vitro (DIV) 14 with Lipofectamine 2000 (Invitrogen). At DIV 17, surface receptors were labeled with anti-GFP antibody for 15 min at room temperature before fixation with 4% PFA in PBS (containing 4% sucrose). Surface receptors were detected by Alexa Fluor 555-conjugated secondary antibody (shown in red in merged picture). After permeabilization with 0.25% Triton X-100 in PBS, the intracellular receptors were labeled with anti-GFP antibody followed by Alexa Fluor 633 or Alexa Fluor 647-conjugated secondary antibody (shown in blue in merged picture). We measured the fluorescence intensity using MetaMorph 6.0 software (Universal Imaging). We analyzed three independent areas per neuron for the quantitation. Intensity is presented as mean ± SEM. We calculated the ratio of the intensity of surface/intracellular in our analyses of surface expression. The number of dendritic spines was measured by cotransferring neurons with pCAG-EGFP and GFP-tagged GluN2B to visualize spines. Spine number was counted in 20 μm secondary dendritic regions of pyramidal neurons. Three regions were selected and averaged for every neuron.

Images were collected using a Zeiss LSM 510 confocal microscope. Serial optical sections at 0.35 μm intervals were used to create maximum projection images. Three to five independent experiments were conducted and significance was analyzed using one-way ANOVA analysis (n = number of cells).

**Two-electrode voltage-clamp (TEVC) current recording and whole-cell voltage-clamp recording.** For this study, we transiently transfected HEK cells with cDNA that encoded a fusion protein of WT or mutant rat GluN2B with a GFP tag (GenBank: NP_036706.1) in the pRK5 vector and WT rat GluN1-1a (hereafter GluN1; GenBank: NP_058706.1). Synthesis and injection of cRNA from WT GluN1 and GluN2B into Xenopus laevis oocytes (Ecocyte), as well as TEVC recordings from oocytes were performed as described previously at 23°C (Hansen et al., 2013). The recording solution contained the following (in mM): 90 NaCl, 1 KCl, 10 HEPES, 0.5 BaCl₂, and 0.01 EDTA, pH 7.4. The membrane potential was held at −40 mV for all TEVC recordings from oocytes unless otherwise stated. The concentration–response curves were fitted with two equations:

\[
\text{Response} = \frac{100\%}{(1 + (\text{EC}_{50}/[\text{agonist}])^N)}
\]

where EC<sub>50</sub> is the concentration of the agonist that induces a half-maximal effect, N is the Hill slope, IC<sub>50</sub> is the concentration of the negative modulators that produces a half-maximal effect, and “minimum” is the degree of residual inhibition at a saturating concentration of the negative modulators.

To evaluate whether the mutants influence the NMDAR response time course, the whole-cell voltage-clamp recordings were performed on transiently transfected HEK 293 cells at −60 mV (23°C). Recording electrodes (3–5 MΩ) were pulled from thin wall glass micropipettes (TW150F-4; World Precision Instruments) using a vertical puller (Narishige P-10) and filled with solution containing the following (in ms): 110 D-glucurate, 110 CsOH, 30 CaCl₂, 5 HEPES, 4 NaCl, 0.5 CaCl₂, 2 MgCl₂, 5 BAPTA, 2 NaATP, and 0.3 NaGTP, pH 7.35. The external solution contained the following (in ms): 150 NaCl, 10 HEPES, 30 D-mannitol, 3 KCl, 1.0 CaCl₂, and 0.01 EDTA, pH 7.4. Rapid solution exchange was performed by computer-controlled piezo-electric solution switching system and data were analyzed by ChanneLab (Synaptosoft) (Yuan et al., 2009). Deactivation or response time course after the rapid removal of glutamate was fitted with the following equation:

\[
\text{Response} = \text{Ampl}_{\text{FAST}} (\exp [-\text{time}/\tau_{\text{FAST}}]) \quad + \quad \text{Ampl}_{\text{SLOW}} (\exp [-\text{time}/\tau_{\text{SLOW}}])
\]

NMDAR-mediated EPSCs were recorded in acute hippocampal slices. Briefly, 300 μm transverse hippocampal slices from postnatal day 13 (P13)–P15 mice were cut on a DTK Microslicer Vibratome (Ted Pella) in chilled sucrose cutting solution containing the following (in ms): 2.5 KCl, 0.5 CaCl₂, 7 MgCl₂, 1.25 NaH₂PO₄, 25 NaHCO₃, 7 glucose, and 210 sucrose. Hippocampal slices were subsequently placed in a chamber with artificial CSF (ACSF) containing the following (in ms): 119 NaCl, 2.5 KCl, 26 NaHCO₃, 1 Na₂PO₄, 11 glucose, 2.5 CaCl₂, and 1.3 MgCl₂ at 32°C for −30 to −60 min. Slices were then maintained at room temperature for 0.5–1 h in the same solution before recording. NMDA EPSCs were
recorded from identified CA1 pyramidal cells using whole-cell patch-clamp methods in the presence of picrotoxin (100 μM) and NBQX (10 μM). Membrane voltage was held at -40 mV and the Schaffer collateral pathway was stimulated at 0.05 Hz with a monopolar glass electrodes filled with ACSF. The internal solution in the patch pipette contained the following (in mM): 135 CsMeSO4, 8 NaCl, 10 HEPES, 0.3 Na3GTP, 4 MgATP, 0.3 EGTA, 5 QX-314, and 0.1 spermine; 3–5 M borosilicate glass pipettes were used for recording. A single weighted decay measure of NMDA EPSCs (referred in the text as decay time; see Cathala et al., 2005) was calculated from the area under the peak-normalized current for 1.3 s after the peak. Series resistance was monitored and not compensated and neurons in which series resistance varied by 25% during a recording session were discarded. Synaptic responses were recorded with a Multiclamp 700B amplifier (Molecular Devices), filtered at 2 kHz, and digitized at 10 Hz. All recordings were performed at room temperature.

In utero electroporation. Pregnant Grin2afl/fl,Grin2bfl/fl mice were anesthetized with isofluorane at E14.5. Each lateral ventricle of the embryo was injected with 2 μl of plasmid DNA with 0.05% fast green (Sigma-Aldrich 68724). After injection, voltage steps (45 V for 5 pulses at 1 Hz with 50 ms) were applied across the uterus to target hippocampal progenitor neurons. Warmed PBS (32°C) was given to moisten the embryos. Buprenex (0.1 mg/kg) was applied and the wound was subsequently sutured.

Results

Surface expression of GluN2B variants in hippocampal neurons

Because GluN2B is critical for development throughout the CNS, it is not surprising that de novo mutations in GluN2B have been identified in a variety of psychiatric and neurological diseases (Hu et al., 2016). We focused on variants within the C terminus because the C termini of the GluN2 subunits are important for the subunit specificity of NMDAR trafficking and signaling (My-
Figure 3. A

The GluN2B C-terminal variants do not change functional properties of NMDARs. Current responses in A–D were recorded under TEVC from Xenopus oocytes to determine pharmacological properties. A, B. Concentration–response curves ($V_{\text{HOLD}} = -40 \text{ mV}$) for glutamate in the presence of 30 μM glycine (A) and glycine in the presence of 100 μM glutamate (B) are shown. C. Concentration–response curves for inhibition of mutant and wild-type NMDA receptors by extracellular Mg$^{2+}$; currents ($V_{\text{HOLD}} = -60 \text{ mV}$) were activated by 100 μM glutamate and 30 μM glycine. D. Mean ratio (in percentage) of the current response to 100 μM glutamate and 30 μM glycine recorded at pH 6.8 and the current response at pH 7.6 ($V_{\text{HOLD}} = -40 \text{ mV}$). E. Superimposed whole-cell current recordings in response to 1000 μM glutamate and 30 μM glycine from HEK cells expressing GluN1/GluN2B ($V_{\text{HOLD}} = -60 \text{ mV}$). F. Weighted mean time constants describing deactivation were not detectably different among the mutations tested. p > 0.05, one-way ANOVA, Bonferroni’s multiple-comparisons test.

Figure 4. The GluN2B C-terminal variants do not change functional properties of NMDARs. Current responses in A–D were recorded under TEVC from Xenopus oocytes to determine pharmacological properties. A, B. Concentration–response curves ($V_{\text{HOLD}} = -40 \text{ mV}$) for glutamate in the presence of 30 μM glycine (A) and glycine in the presence of 100 μM glutamate (B) are shown. C. Concentration–response curves for inhibition of mutant and wild-type NMDA receptors by extracellular Mg$^{2+}$; currents ($V_{\text{HOLD}} = -60 \text{ mV}$) were activated by 100μM glutamate and 30 μM glycine. D. Mean ratio (in percentage) of the current response to 100 μM glutamate and 30 μM glycine recorded at pH 6.8 and the current response at pH 7.6 ($V_{\text{HOLD}} = -40 \text{ mV}$). E. Superimposed whole-cell current recordings in response to 1000 μM glutamate and 30 μM glycine from HEK cells expressing GluN1/GluN2B ($V_{\text{HOLD}} = -60 \text{ mV}$). F. Weighted mean time constants describing deactivation were not detectably different among the mutations tested. p > 0.05, one-way ANOVA, Bonferroni’s multiple-comparisons test.

ers et al., 2011; Tarabeux et al., 2011; Parsons et al., 2008; and COSMIC database). We selected variants within the last 68 aa of the GluN2B C-terminal domain, which were identified in patients with schizophrenia, autism spectrum disorders (ASDs), and mental retardation (Fig. 1 A, B). The relevant residues in GluN2B are shown in Figure 1A. To determine whether these variants in the GluN2B C terminus alter GluN2B trafficking to the surface, we generated three rat mutant GluN2B subunits using site-directed mutagenesis to introduce the following missense changes: S1413L, L1422F, and S1450F (S1415L, L1424F, and S1452F in human, respectively). All GluN2B cDNAs were engineered to produce a fusion protein that contained a GFP tag appended in-frame to the N-terminal domain to allow for detection of surface NMDARs using immunofluorescence microscopy. We expressed each GluN2B mutant transiently in cultured rat hippocampal neurons and labeled surface receptors with GFP antibody followed by fixation. Subsequently, we applied GFP primary antibody again to label the intracellular pool and used a secondary antibody conjugated to a different chromophore to visualize intracellular immunoreactivity (Fig. 1C). We compared the ratio of surface GluN2B versus intracellular receptors. Among the mutants tested, only GluN2B S1413L displayed a statistically significant deficit in surface expression (30% reduction) compared with GluN2B WT (Fig. 1D). The other GluN2B mutants displayed no significant change in surface expression.

**Several GluN2B C-terminal variants disrupt binding to MAGUKs**

The GluN2B subunit binds to a variety of MAGUK proteins via a direct interaction between the last 4 aa (ESDV), often referred to as the PDZ ligand, and the PDZ domains of MAGUKs. The PDZ ligand on GluN2B stabilizes NMDARs on the cell surface. Moreover, the synaptic expression of NMDARs is stabilized via binding to PSD-95. To test whether the three variants affect PSD-95 or SAP102 binding to GluN2B, we generated GST-GluN2B C-terminal fusion proteins with single variants in the GluN2B tail. We used a fusion protein containing the last 179 aa of GluN2B, as described previously (Sanz-Clemente et al., 2010), to compare WT GST-GluN2B (including aa 1315–1482) to the GluN2B harboring S1413L, L1422F, or S1450F variants. We conducted pull-down assays with the WT or mutant GST-GluN2B fusion proteins using lysates from rat brain P2 fractions and probed for PSD-95 or SAP102. Interestingly, all three GluN2B mutant GST fusion proteins showed impaired binding to both PSD-95 and SAP102 (Fig. 2A,B). The GST-GluN2B S1413L, L1422F, and S1450F binding was reduced by ~50% (Fig. 2C,D). As shown been reported previously, GST-GluN2B truncated to exclude the PDZ ligand by the introduction of a stop codon at Ser1482 (ΔSTOP) disrupts MAGUK binding. Therefore, we used this truncated version of GluN2B as a comparison for impaired binding (Fig. 2C,D).

**Reduced spine number in GluN2B S1413L-expressing neurons**

Because reduced surface expression of GluN2B is often associated with other physiological changes, we next investigated the dendritic morphology of neurons expressing the three GluN2B mutants (S1413L, L1422F, or S1450F) that had shown a clear phenotype in our biochemical assays. EGFP was coexpressed with GluN2B, as described previously (Sanz-Clemente et al., 2010), and visualized intracellular immunoreactivity (Fig. 1C). We compared the ratio of surface GluN2B versus intracellular receptors. Among
NMDAR pharmacological properties and response time course are not affected by the GluN2B C-terminal variants

We next tested whether the three GluN2B mutants (S1413L, L1422F, and S1450F) that had impaired MAGUK binding also displayed altered pharmacological properties. We coexpressed GluN2B (WT, S1413L, L1422F, or S1450F) with GluN1 in X. laevis oocytes and performed TEVC recordings. We determined the agonist potencies (EC₅₀ value), the potentiation for inhibition by extracellular magnesium (IC₅₀; Fig. 4C), and the proton sensitivity (percentage inhibition by pH 6.8 vs. pH 7.6; Fig. 4D). Except for a modest decrease of glutamate potency (increased EC₅₀ value; Table 1) in the mutant L1422F and a mild increase of glycine potency (decreased EC₅₀ value; Table 1) in the mutant S1450F, the data indicated that the major pharmacological properties remain unchanged in NMDARs containing any of these three variants.

In addition, we assessed the effect of the three variants within the GluN2B C terminus on the response amplitude and time course of NMDARs. The NMDAR current—response time course after glutamate removal (in the presence of saturating glycine) is thought to determine the time course of the synaptic current (Lester et al., 1990). We therefore recorded the current response under voltage clamp from HEK cells transiently cotransfected with GluN1 plus mutant or WT GluN2B during rapid solution exchange. The deactivation time course of all three NMDARs variants after the removal of glutamate could be described by two exponential components, which were similar to GluN2B WT receptors (Fig. 4E, F; Table 2). No significant differences were detected among any fitted parameters (Table 2). In addition, there were no detectable differences in the response amplitude, response rise time, or charge transfer during brief glutamate application. Together, these data suggest that these three rare variants do not change NMDAR pharmacology, response amplitude, or response time course significantly.

NMDAR currents are impaired in GluN2B S1413L-expressing neurons

Our data showed that, compared with GluN2B WT, GluN2B S1413L displays lower surface expression (Fig. 1), impaired binding to MAGUKs (Fig. 2), and decreased dendritic spine density (Fig. 3). From these data, we would predict that synaptic current responses would be reduced if not confounding changes in receptor function produced by these amino acid substitutions. Our functional analysis should allow us to interpret any change in synaptic response amplitude or time course as being reflective of the number of receptors because we know that the variants have no effect on NMDAR time course, amplitude, or agonist potency. We therefore designed a series of experiments to assess whether mutant GluN2B would alter the synaptic current response properties. We used GRIN2A⁻/⁻/GRIN2B⁻/⁻ mice to perform molecular replacement experiments (Gray et al., 2011). Because GluN2A and GluN2B are expressed in principal cells of the hippocampus, deletion of these subunits should eliminate NMDAR currents. In agreement with previous reports (Gray et al., 2011), electrophysiological analysis in CA1 pyramidal neurons in acute hippocampal slices showed that the NMDA EPSCs were lost in Cre-mCherry-positive neurons (Fig. 5A). In addition, transient transfection of neurons with WT GluN2B fully rescued NMDA EPSCs in Cre-expressing GRIN2A⁻/⁻/GRIN2B⁻/⁻ cells, as assessed by comparison of EPSC response amplitudes. In contrast, transient transfection of neurons with GluN2B S1413L restored only ~60% of the NMDA EPSCs in Cre-positive GRIN2A⁻/⁻/GRIN2B⁻/⁻ neurons (Fig. 5B, C), NMDA EPSC decay time was not altered by the GluN2B S1413L variant compared with GluN2B (Fig. 5D). Because GluN2B S1413L has no effect on NMDAR response properties or amplitudes, these deficits in synaptic currents are consistent with deficits in synaptic targeting.

Discussion

Many lines of evidence support a critical role for synaptic dysfunction in the etiology of a variety of cognitive disorders (Zoghbi and Bear, 2012; Cooke and Bear, 2012; Morrison and Baxter, 2012; Nithanathanarajah and Hannan, 2013; Buffington et al., 2014; Balu and Coyle, 2015). Synaptic proteins including receptors, adhesion molecules, and scaffolding proteins have been shown to be involved in regulating synaptic transmission and plasticity (Fields and Itoh, 1996; Yang et al., 2004; Derkach et al., 2007; Dityatev et al., 2008; Xu, 2011; Verpelli et al., 2012; Ebert and Greenberg, 2013; Fan et al., 2014). Postsynaptic NMDARs are essential for synaptic development and plasticity and their dysfunction has been implicated in neurological and psychiatric diseases.

Recently, it has become possible to evaluate genetic variation in the healthy human population through extensive exome sequencing. At present, 425 missense variants have been identified in the healthy human population through extensive exome sequencing. At present, 425 missense variants have been identified in the healthy human population through extensive exome sequencing. At present, 425 missense variants have been identified in the healthy human population through extensive exome sequencing.
Indeed, loss-of-function variants are likely deleterious given that GluN2B is essential for viability in mice.

Whole-exome sequencing has also produced an enormous amount of data linking genetic composition to disease phenotype. Missense mutations located both in extracellular domains and transmembrane elements have been identified in patient cohorts with developmental disability or delays, epileptic encephalopathy, autism spectrum disorders (ASDs), and Alzheimer’s disease (Endele et al., 2010; Tarabeux et al., 2011; de Ligt et al., 2012; Lemke et al., 2013; Lesca et al., 2013; Andreoli et al., 2014; Lemke et al., 2014; Fromer et al., 2014; Zhu et al., 2015; Swanger et al., 2016; for review, see Yuan et al., 2015 and Hu et al., 2016). Although there are a growing number of variants being identified in patients with neurological disease, functional data exist for <10% of the rare variants and de novo mutations reported for the GRIN family of genes. To understand whether the pathophysiology results from changes in mutant receptor response properties, functional evaluation of the mutant receptors is necessary.

The C terminus shows substantial genetic variation and largely appears tolerant to genetic changes (Swanger et al., 2016). However, numerous sites for post-translational modification and binding to intracellular scaffolding proteins exist in this region, suggesting that some variants could influence receptor function and thus human disease. Despite the description of numerous variants in the C terminus (Yuan et al., 2015; Hu et al., 2016), there has yet to be any systematic exploration of the effect on NMDAR localization or function for any of the variants located in the C terminus. We have examined several missense variants in the GluN2B C-terminal domain to evaluate potential phenotypes in trafficking, synaptic protein binding, and function. Our results show clear changes in surface expression and subcellular localization that could contribute to patient phenotypes.

We targeted rare missense variants located in the C terminus of GluN2B, none of which had been studied using either in vitro or in vivo functional assays. Our rationale was twofold. First, we hoped to learn about the molecular consequences of these variants that could provide insight into the underlying pathophysiology of disease. Second, because the C termini of NMDAR are large and hard to evaluate systematically regarding their role in trafficking and functional modulation, we hypothesized that targeting critical residues revealed from patient sequencing would provide a powerful clue to

the exome places GRIN2B in the top 1 percentile in terms of intolerance (Petrovski et al., 2013). Furthermore, there are regions of extreme intolerance to variation within the protein, including the transmembrane helices, which show virtually no variants in the healthy population (Swanger et al., 2016; Ogden et al., 2017).
understanding molecular determinants that might influence NMDAR synaptic expression and/or functional properties.

We focused on specific residues within the GluN2B C terminus that might affect trafficking and synaptic function and first evaluated surface expression and MAGUK binding in a preliminary screen, which allowed us to narrow the study to three specific variants. Among these three rare variants, we found one that had clear deficits in plasma membrane expression, as well as a decrease in MAGUK binding. Our findings are consistent with human GluN2B S1415L, L1424, and S1452 affecting MAGUK binding to the GluN2B C terminus. It may seem unexpected that all three of the variants evaluated had defects in MAGUK binding because none was within the PDZ ligand. However, there are residues upstream of the PDZ ligand that regulate non-PDZ binding to SAP102 (Chen et al., 2011) as well as PSD-95 (Cousins and Stephenson, 2012). The variants in the cluster between S1415 and S1452 may be involved in structural or posttranslational regulation of the primary MAGUK-binding region.

Only one mutant evaluated, GluN2B S1415L, showed defects in both surface expression and spine density. It is interesting that this variant was identified in an autism patient because spine changes are often implicated in autism spectrum disorders (ASDs). In many cases, there is an overabundance of spines, especially in cortical pyramidal neurons in autism patients and animal models (Comery et al., 1997; Irwin et al., 2000; Hutsler and Zhang, 2010; Penzes et al., 2011; Santini et al., 2013; Tang et al., 2014), but deficits are also reported (Zoghbi and Bear, 2012; Belichenko et al., 2009). For example, spine density is largely increased in tuberous sclerosis neurons, whereas it is reduced in Angelman syndrome and Down syndrome neurons (Tang et al., 2014; Hethorn et al., 2015; Belichenko et al., 2004). In one of the most popular ASD animal models, Shank3 KO mice have decreased spine density in striatal medium spiny neurons (Peça et al., 2011). Similarly, loss-of-function Shank3 plays a dominant-negative role in regulating spine number (Durand et al., 2012). Interestingly, increased spine density was observed in Purkinje cells of TSC1-null mice (Tsai et al., 2012), whereas reduction of spine density was reported in hippocampal and cortical neurons lacking TSC1 (Tavaiozie et al., 2005; Meikle et al., 2008). However, the same group reported no change in spine density or morphology of acute loss of Tsc1 neuron in slices and suggested that this was due to different hippocampal activity levels in vivo and in slice cultures (Bateup et al., 2011). In addition, a mutation in neureolin 4X identified in an autistic patient is associated with changes in the number of functional spines (Bemben et al., 2015). Therefore, there are a variety of examples of aberrant spine density in animal models of ASDs and our findings support a model in which GluN2B dysfunction contributes to a dendritic spine deficit in ASDs.

In addition to changes in spine density, there are also reports of changes in spine morphology or dendritic arborizations. For example, in both Fragile X and Rett syndrome, there is no change in spine number, but rather a change in spine morphology with more filopodia-like and thin spines (Phillips and Pozzo-Miller, 2015). In addition, the Shank3 KO mouse model displays increases in dendritic arborizations. Indeed, there is evidence that both NMDAR function and MAGUK binding are important determinants in regulating dendritic spine morphology (Chen et al., 2011). Our finding that GluN2B S1413L affects spine density is consistent with the overall literature of spine phenotypes with ASD. More precise studies on potential effects of this variant on dendritic complexity or changes in spine morphology are important topics for further studies.

We observed a variety of abnormal phenotypes for GluN2B S1413L, including deficits in NMDAR trafficking, synaptic NMDAR currents, and spine density. What might be the molecular basis for these deficits? This residue is not part of any known motif or previously described binding domain. Although serines are often targets for phosphorylation, we did not find S1413 to be a phosphorylated residue in any database or in the literature (for review, see Sanz-Clemente et al., 2013a). To test this, we performed immunoprecipitation of native GluN2B from mouse brain synapticosomal fractions and evaluated using mass spectrometry, but also did not find S1413 to be phosphorylated in vivo under basal conditions (S.L., unpublished results). However, we certainly cannot exclude the possibility that synaptic activity during development might trigger phosphorylation of this residue by an unidentified kinase.

In summary, we have used information from whole-exome sequencing or Sanger sequencing of NMDAR genes of patients to investigate mechanisms underlying NMDAR dysfunction. Specifically, we found that three GRIN2B missense variants generated GluN2B subunits that exhibited deficient binding to MAGUKs. In addition, surface expression of one variant, GluN2B S1413L, was significantly reduced. We also found that S1413L affected spine density. Furthermore, we found that GluN2B S1413L resulted in a deficit in the rescue of NMDAR synaptic currents in mice, but was without effect on normal NMDAR function. This result is consistent with a deficit in the number of synaptic NMDARs. Together, these data support the idea that this variant has multiple effects on protein binding and synaptic function that could be relevant to spine function.

Autism is a disorder thought to involve dysfunction at the level of the spine. In an autistic spectrum disorder cohort study, human GluN2B S1415L was found in one of 428 ASD patients and was inherited from one parent (validated by Sanger sequencing). This variant was absent in 283 Caucasian control individuals (Endele et al., 2010; Tarabeux et al., 2011) and was neither annotated in dbSNP nor reported in ClinVar. It is not observed in 1000 Genomes and National Heart, Lung, and Blood Institute Exome Sequencing Project. Two individuals of South Asian descent reported with this variant in the gnomAD browser were identified with low confidence based on the quality of the data. Although we lack the clinical information to determine pathogenicity of human S1415L, our functional assays on rodent S1413L reveal a possible mechanism whereby a single amino acid substitution in the GluN2B C terminus could alter synaptic and spine function and thus potentially contribute to diseases with complex genetics such as ASD. Further studies are needed to fully understand how this single variant might affect neural function.

References
Belichenko et al., 2009
Chen et al., 2011

4100 • J. Neurosci., April 12, 2017 • 37(15):4093–4102 Liu et al. • Rare Variant Identified Within the GluN2B C-Terminus


Liu et al. Rare Variant Identified Within the GluN2B C-Terminus. J. Neurosci., April 12, 2017 • 37(15):4093–4102 • 4101


Nithyanantharajah J, Hannon AJ (2013) Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as...


Tarabeux J, et al. (2011) Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry 1:e55. CrossRef Medline


